Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions.

The formation of amyloid fibril is associated with major human diseases, including Alzheimer's disease, prion diseases, and type 2 diabetes. Methods for efficient inhibition of amyloid fibril formation are therefore highly clinically important. A principal approach for the inhibition of amyloid formation is based on the use of modified molecular recognition elements. Here, we demonstrate efficient inhibition of amyloid formation of the type 2 diabetes-related human islet amyloid polypeptide (hIAPP) by a modified aromatic peptide fragment and a small aromatic polyphenol molecule. A molecular recognition assay using peptide array analysis suggested that molecular recognition between hIAPP and its core amyloidogenic module is mediated by aromatic rather than hydrophobic interactions. To study the possible effect of aromatic interactions on inhibition of hIAPP fibril formation, we have used peptide and small molecule inhibitors. The addition of a nonamyloidogenic peptide analogue of the core module NFGAILSS, in which phenylalanine was substituted with tyrosine (NYGAILSS), resulted in substantial inhibition of fibril formation by hIAPP. The inhibition was significantly stronger than the one achieved using a beta-sheet breaker-conjugated peptide NFGAILPP. On the basis of the molecular arrangement of the tyrosine-phenylalanine interaction, we suggest that the inhibition stems from the geometrical constrains of the heteroaromatic benzene-phenol interaction. In line with this notion, we demonstrate remarkable inhibition of hIAPP fibril formation and cytotoxicity toward pancreatic beta-cells by a small polyphenol molecule, the nontoxic phenol red compound. Taken together, our results provide further experimental support for the potential role of aromatic interactions in amyloid formation and establish a novel approach for its inhibition.

[1]  G. Cooper,et al.  ULTRASTRUCTURAL EVIDENCE THAT APOPTOSIS IS THE MECHANISM BY WHICH HUMAN AMYLIN EVOKES DEATH IN RINm5F PANCREATIC ISLET β‐CELLS , 2001, Cell biology international.

[2]  Ehud Gazit,et al.  A possible role for π‐stacking in the self‐assembly of amyloid fibrils , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Meital Reches,et al.  Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin* , 2002, The Journal of Biological Chemistry.

[4]  S. Radford,et al.  Responsive gels formed by the spontaneous self-assembly of peptides into polymeric β-sheet tapes , 1997, Nature.

[5]  Meital Reches,et al.  Amyloidogenic hexapeptide fragment of medin: homology to functional islet amyloid polypeptide fragments , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[6]  C. Hunter Arene—Arene Interactions: Electrostatic or Charge Transfer? , 1993 .

[7]  J. Fraser Stoddart,et al.  π–π INTERACTIONS IN SELF‐ASSEMBLY , 1997 .

[8]  C. Dobson Protein folding and misfolding , 2003, Nature.

[9]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[10]  H. Lashuel,et al.  New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. , 2002, The Journal of biological chemistry.

[11]  C. Betsholtz,et al.  Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. , 1989, The New England journal of medicine.

[12]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[13]  B. Ahrén,et al.  Islet amyloid and type 2 diabetes mellitus. , 2000, The New England journal of medicine.

[14]  Susan Jones,et al.  Amyloid-forming peptides from beta2-microglobulin-Insights into the mechanism of fibril formation in vitro. , 2003, Journal of molecular biology.

[15]  J. Bernhagen,et al.  Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. , 2000, Journal of molecular biology.

[16]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[17]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[18]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[19]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[20]  E. Gazit,et al.  The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. , 2003, Biochemistry.

[21]  Sharon Gilead,et al.  Identification and characterization of a novel molecular-recognition and self-assembly domain within the islet amyloid polypeptide. , 2002, Journal of molecular biology.

[22]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[23]  P. Lansbury,et al.  Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. , 2002, Biochemistry.

[24]  L. Rossetti,et al.  Functional analysis of a conditionally transformed pancreatic beta-cell line. , 1998, Diabetes.

[25]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Harroun,et al.  Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation , 2001, FEBS letters.

[27]  A. Takashima,et al.  Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease , 2003, Journal of neurochemistry.

[28]  E. Gazit,et al.  Completely different amyloidogenic potential of nearly identical peptide fragments. , 2003, Biopolymers.

[29]  James C. Sacchettini,et al.  Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.

[30]  Meital Reches,et al.  Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes , 2003, Science.

[31]  G. Cooper,et al.  Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid. , 2003, The Biochemical journal.

[32]  A. Kapurniotu,et al.  Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. , 2001, Biopolymers.

[33]  M. Findeis,et al.  Modified-peptide inhibitors of amyloid beta-peptide polymerization. , 1999, Biochemistry.

[34]  F. Gervasio,et al.  Stacking and T-shape competition in aromatic-aromatic amino acid interactions. , 2002, Journal of the American Chemical Society.

[35]  Andreas Hoenger,et al.  De novo designed peptide-based amyloid fibrils , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Fraser,et al.  Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. , 2002, Journal of molecular biology.

[37]  Ehud Gazit,et al.  Analysis of the Minimal Amyloid-forming Fragment of the Islet Amyloid Polypeptide , 2001, The Journal of Biological Chemistry.